HealthMay 15, 2026FDA Withholds Accelerated Approval for Replimune’s RP1 Melanoma Treatment; Agency Leadership Changes Cited in CriticismThe FDA declined to grant accelerated approval to Replimune's investigational melanoma treatment RP1 after the company sought approval based on a single-arm trial in...Food and Drug Administration (FDA)ReplimuneRP1
